Seven Eight Capital’s Pacira BioSciences PCRX Stock Holding History

Seven Eight Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,500	Closed	-$394K	–	621
2020 Q2	$394K	Buy	+7,500	New	+$313K	0.29%	123
2020 Q1	–	Sell	-15,886	Closed	-$720K	–	633
2019 Q4	$720K	Sell	15,886 -16,589	-51%	-$705K	0.04%	488
2019 Q3	$1.24M	Buy	32,475 +2,200	+7%	+$87.8K	0.07%	393
2019 Q2	$1.32M	Buy	+30,275	New	+$1.29M	0.07%	352
2018 Q4	–	Sell	-6,275	Closed	-$308K	–	670
2018 Q3	$308K	Buy	+6,275	New	+$271K	0.02%	511
2017 Q3	–	Sell	-957	Closed	-$46K	–	566
2017 Q2	$46K	Buy	+957	New	+$44.4K	0.01%	486
2017 Q1	–	Sell	-2,401	Closed	-$78K	–	640
2016 Q4	$78K	Sell	2,401 -5,500	-70%	-$184K	0.02%	476
2016 Q3	$270K	Buy	7,901 +6,000	+316%	+$235K	0.08%	286
2016 Q2	$64K	Buy	+1,901	New	+$93.4K	0.02%	435
2016 Q1	–	Sell	-801	Closed	-$62K	–	650
2015 Q4	$62K	Buy	801 +800	+80,000%	+$45.3K	0.04%	415
2015 Q3	$0	Buy	+1	New	+$61	﹤0.01%	646
2015 Q2	–	Sell	-601	Closed	-$53K	–	634
2015 Q1	$53K	Buy	+601	New	+$61K	0.09%	280
2014 Q4	–	Sell	-3,501	Closed	-$339K	–	609
2014 Q3	$339K	Buy	+3,501	New	+$341K	0.26%	136
2014 Q2	–	Sell	-10,100	Closed	-$707K	–	579
2014 Q1	$707K	Buy	+10,100	New	+$687K	0.61%	40

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Seven Eight Capital's PCRX Position: Q3 2020 in Review

Seven Eight Capital sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 7,500 shares — an estimated $394K sold.

Seven Eight Capital first reported a position in PCRX in Q1 2014 and held it in 14 quarters. The position peaked at $1.32M in Q2 2019. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

Seven Eight Capital reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
Seven Eight Capital sold 7,500 Pacira BioSciences shares in Q3 2020, an estimated $394K.
Seven Eight Capital first reported a position in Pacira BioSciences in Q1 2014 and held it in 14 quarters.
Seven Eight Capital's Pacira BioSciences position peaked at $1.32M in Q2 2019.
257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Seven Eight Capital's 13F filing for Q3 2020, filed 16 Nov 2020.